Pharmacelsus’ GLP implementation exemplary for European CROs
Pharmacelsus obtained GLP-certification covering the complete portfolio in November 2008. The company is not only able to perform accompanying analytical services for clinical studies in addition to its preclinical services, but also decided to share its knowledge on the GLP implementation process with other laboratories. Thirteen scientists of the European Commission Joint Research Center came to learn more about Pharmacelsus’ solution for the implementation of a GLP system in an in vitro laboratory.
During a three days hands-on training, they glanced at the lab-life in theory and practice, especially focusing the GLP relevant implementation on in vitro toxicology and bioanalytics. The practical course provided the opportunity for staff of all levels to understand the importance and relevance of GLP compliance, and how to apply the requirements of GLP into their everyday work in an in vitro laboratory.
Pharmacelsus cooperates with ECVAM in the framework of an international pre-validation study in the field of human metabolism and toxicity which is supervised by ECVAM.
Pharmacelsus holds the statement of GLP compliance for categories 2 (toxicity studies), 8 (analytical and clinical chemistry testing) and 9 (other studies: pharmacodynamic, pharmacokinetic, metabolical and toxicological testing). Because of the GLP status, the company is now able to perform accompanying analytical services for clinical studies in addition to its preclinical services.
Other news from the department politics & laws
These products might interest you

HUMIPLATE by ACARYON
Get new insights on the health promoting properties of your product(s)
Customized Studies – Tailored to Your Needs

Genomics & Analytical Services by Azenta
Integrated Genomics & Analytical Services from Azenta Life Sciences
Discovery can be challenging work. Until you find the right genomics partner.

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Demonic_Males:_Apes_and_the_Origins_of_Human_Violence
CSIRO Molecular and Health Technologies - Clayton North, Australia
LDC Receives 1 Million Euros from the Max Planck Foundation for the Development of New Drug Candidates
Team Led by Scripps Research Scientists Uncovers New Way to Limit Damaging Production of Nitric Oxide - Results Could Lead to New Treatments for Conditions From Inflammation to Cancer
Successful Pilot Study for Non-Invasive Prenatal Diagnostic Test to Determine Trisomy 21
